Implementation of prophylactic HPV vaccination: progress and future challenges

References

• FrancoEL, Coutlée F, Ferenczy A. Integrating human papillomavirus vaccination in cervical cancer control programmes. Pub. Health Genomics12, 352–361 (2009).
   PubMedGoogle Scholar
• Cuzick J, Castañón A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK. Br. J. Cancer102, 933–939 (2010).
   PubMed Web of Science ®Google Scholar
• Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine24, 106–113 (2006).
   PubMed Web of Science ®Google Scholar
• Stern PL, Kitchener HC. Vaccines for the Prevention of Cervical Cancer. Oxford University Press, Oxford, UK (2009).
   Google Scholar
• Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin. Diagn. Lab. Immunol.4, 122–126 (1997).
   PubMedGoogle Scholar
• Viscidi RP, Schiffman M, Hildesheim A et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol. Biomarkers Prev.13, 324–327 (2004).
   PubMed Web of Science ®Google Scholar
• Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. Virology77, 13125–13135 (2003).
   Google Scholar
• Richards RM, Lowy DR, Schiller JT, Day PM. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl Acad. Sci. USA103, 1522–1527 (2006).
   PubMed Web of Science ®Google Scholar
• Roberts JN, Buck CB, Thompson CD et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med.13, 857–861 (2007).
   PubMed Web of Science ®Google Scholar
• Conway MJ, Meyers C. Replication and assembly of human papillomaviruses. J. Dent. Res.88, 307–317 (2009).
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ et al. Comparison of the immunogenicity and safety of Cervarix® and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum. Vaccin.5, 705–719 (2009).
   PubMed Web of Science ®Google Scholar
• Prakash M, Patterson S, Kapembwa MS. Macrophages are increased in cervical epithelium of women with cervicitis. Sex. Transm. Infect.77, 366–369 (2001).
   PubMedGoogle Scholar
• Muñoz N, Bosch FX, Castellsagué X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer111, 278–285 (2004).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95, 1459–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Olsson SE, Villa LL, Costa RL et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine25, 4931–4939 (2007).
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356, 1915–1927 (2007).
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet369, 1861–1868 (2007).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367, 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Schwarz TF. Human papillomavirus-16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer. Expert Rev. Obstet. Gynecol.2, 293–303 (2007).
   Google Scholar
• The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet374, 1975–1985 (2009).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet369, 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• David MP, Van Herck K, Hardt K et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol. Oncol.115(3 Suppl.), S1–S6 (2009).
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Block SL, Lazcano-Ponce E et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6,11,16,18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr. Infect. Dis. J.26, 201–209 (2007).
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health40, 564–571 (2007).
   PubMed Web of Science ®Google Scholar
• Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008. Vaccine26, 6529–6541 (2008).
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Spaczynski M, Schneider A et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine27581–587 (2009).
   PubMed Web of Science ®Google Scholar
• Munoz N, Manalastas R Jr, Pitisuttihum P et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women ages 24–45 years: a randomised, double-blind trial. Lancet 373, 1949–1957 (2009).
   Google Scholar
• Grainge MJ, Seth R, Guo L et al. Cervical human papillomavirus screening among older women. Emerg. Infect. Dis.11, 1680–1685 (2005).
   PubMed Web of Science ®Google Scholar
• Olsson SE, Kjaer SK, Sigurdsson K et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccin.5(10), 696–704 (2009).
   PubMed Web of Science ®Google Scholar
• Bosch FX, Burchell AN, Schiffman M et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine265, K1–K16 (2008).
   Google Scholar
• Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J. Infect. Dis.200, 166–171 (2009).
   PubMed Web of Science ®Google Scholar
• Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81, 8784–8792 (2007).
   Google Scholar
• Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet374, 301–314 (2009).
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer S, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J. Infect. Dis.199, 926–935 (2009).
   PubMed Web of Science ®Google Scholar
• Wheeler, CM, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J. Infect. Dis.199, 936–944 (2009).
   PubMed Web of Science ®Google Scholar
• Harper DN. Current prophylactic HPV vaccines and gynecologic premalignancies. Curr. Opin. Obstet. Gynecol.21(6), 457–464 (2009).
   PubMed Web of Science ®Google Scholar
• Descamps D, Hardt K, Spiessens B et al. Safety of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum. Vaccine5, 332–340 (2009).
   PubMed Web of Science ®Google Scholar
• Wacholder S, Chen BE, Wilcox A et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized controlled trials. Br. Med. J.340, c712 (2010).
   PubMed Web of Science ®Google Scholar
• Dana A, Buchanan KM, Goss MA et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet. Gynecol.114, 1170–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Brabin L, Roberts SA, Stretch R et al. A survey of adolescent experiences of human papillomavirus vaccination in the Manchester study. Br. J. Cancer101, 1502–1504 (2009).
   PubMed Web of Science ®Google Scholar
• Reid M. Report of an attitudinal study to inform Year 2 of the HPV immunisation programme in Scotland. NHS Health Scotland, Edinburgh, Scotland (2009).
   Google Scholar
• Lenselink CH, Gerrits MMJG, Melchers WJG, Massuger LFAG, Van Hamont D, Bekkers RLM. Parental acceptance of human papillomavirus vaccine. Eur. J. Obstet. Gynecol. 137, 103–107 (2008).
   Google Scholar
• Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am. J. Epidemiol.171, 357–367 (2010).
   PubMed Web of Science ®Google Scholar
• Lévy-Bruhl D, Bousquet V, King LA et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Eur. J. Cancer45, 2709–2713 (2009).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med.359, 821–822 (2008).
   PubMed Web of Science ®Google Scholar
• Zechmeister I, Freiesleben de Blasio B, Garnett G. HPV-vaccination for the prevention of cervical cancer in Austria: a model based long-term prognosis of cancer epidemiology. J. Pub. Health18, 3–13 (2010).
   Google Scholar
• CDC. National, state and local area vaccination coverage among adolescents aged 13–17 years – United States, 2008. MMWR Morb. Mortal. Wkly Rep.58, 997–1001 (2009).
   PubMedGoogle Scholar
• Markowitz LE, Hariri S, Unger ER, Saraiya M, Deblina Datta S, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine28(30), 4731–4737 (2010).
   PubMed Web of Science ®Google Scholar
• Simoens C, Sabbe M, Van Damme P, Beutels P, Arbyn M. Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007–2008. Eurosurveillance14, 1–4 (2009).
   Google Scholar
• Jit M, Vyse A, Borrow R, Pebody R, Soldan K, Miller E. Prevalence of human papillomavirus antibodies in young female subjects in England. Br. J. Cancer97, 989–991 (2007).
   PubMed Web of Science ®Google Scholar
• Roberts SA, Brabin L, Stretch R et al. Human papillomavirus vaccination and social inequality: results from a prospective cohort study. Epidemiol. Infect. DOI: 10.1017/S095026881000066X (2010) (Epub ahead of print).
   Google Scholar
• Mixer RE, Jamrozik K, Newsom D. Ethnicity as a correlate of the uptake of the first dose of mumps, measles and rubella vaccine. J. Epidemiol. Comm. Health61, 797–801 (2007).
   PubMedGoogle Scholar
• Hilton S, Hunt K, Langan M, Bedford H, Petticrew M. Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005–2008). Soc. Sci. Med.70, 942–950 (2010).
   PubMed Web of Science ®Google Scholar
• Mortenson GL. Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study. BMC Pub. Health10, 68 (2010).
   PubMedGoogle Scholar
• Rondy M, Van Lier A, Van de Kassteele J, Rust L, De Melker H. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine28, 2070–2075 (2010).
   PubMed Web of Science ®Google Scholar
• Brotherton JML, Mullins R. Estimating coverage of the National HPV Vaccination Program: where are we at? Med. J. Aust.19, 188 (2009).
   Google Scholar
• Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papillomavirus school vaccination program in South Australia. Aust. N. Z. J. Pub. Health33, 365–370 (2009).
   PubMed Web of Science ®Google Scholar
• Weisberg E, Bateson D, McCaffery K, Skinner S. HPV vaccination catch up program. Utilisation by young Australian women. Aust. Fam. Phys.38, 72–76 (2009).
   PubMed Web of Science ®Google Scholar
• Ogilvie G, Anderson M, Marra F et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med.7, e1000270 (2010).
   PubMed Web of Science ®Google Scholar
• Brabin L, Roberts RA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine24, 3087–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Marlow LA, Waller J, Wardle J. Parental attitudes to pre-pubertal HPV vaccination. Vaccine25, 1945–1952 (2007).
   PubMed Web of Science ®Google Scholar
• Pruitt SL, Schootman M. Geographic disparity, area poverty, and human papillomavirus vaccination. Am. J. Prev. Med.38, 525–533 (2010).
   PubMed Web of Science ®Google Scholar
• Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J. Adolesc. Health45, 453–462 (2009).
   PubMed Web of Science ®Google Scholar
• Reiter PL, Brewer NT, Gottlieb SL, McRee A-L, Smith JS. Parent’s health beliefs and HPV vaccination of their adolescent daughters. Soc. Sci. Med.69, 475–480 (2009).
   PubMed Web of Science ®Google Scholar
• Bach PB. Gardasil: from bench, to bedside, to blunder. Lancet375, 593–594 (2010).
   Google Scholar
• Szilagyi P, Vann J, Bordley C et al. Interventions aimed at improving immunization rates. Cochrane Database Syst. Rev.4, CD003941 (2002).
   Google Scholar
• Fang CY, Coups EJ, Heckman CJ. Behavioral correlated of HPV vaccine acceptability in the 2007 Health Information National Trends Survey (HINTS). Cancer Epidemiol. Biomarkers Prev.19, 319–326 (2010).
   PubMedGoogle Scholar
• Schnatz PF, Humphrey K, O’Sullivan DM. Assessment of the perceptions and administration of the human papillomavirus vaccine. J. Low. Gen. Tract Dis.14, 103–107 (2010).
   PubMed Web of Science ®Google Scholar
• Stretch R, McCann R, Roberts SA, Elton P. Baxter D, Brabin L. A qualitative study to assess school nurses’ views on vaccinating 12–13 year old school girls against human papillomavirus without parental consent. BMC Pub. Health9, 254 (2009).
   PubMedGoogle Scholar
• Mehu-Parant F, Rouzier R, Soulat J-M, Parant O. Eligibility and willingness of first-year students entering university to participate in a HPV vaccination catch-up program. Eur. J. Obstet. Gynecol. Rep. Biol.148, 186–190 (2010).
   PubMed Web of Science ®Google Scholar
• Forster AS, Marlow LAV, Wardle J, Stephenson J, Waller J. Understanding adolescents’ intentions to have the HPV vaccine. Vaccine28, 1673–1676 (2010).
   PubMedGoogle Scholar
• Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet. Gynecol.111, 1103–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Allen JD, Mohllajee AP, Shelton RC, Othus MKD, Fontenot HB, Hanna R. Stage of adoption of the human papillomavirus vaccine among college women. Prev. Med.45, 420–425 (2009).
   Google Scholar
• Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD. Predictors of HPV vaccine among women aged 19–26: importance of a physician’s recommendation. Vaccine DOI: 1010.6/j.vaccine.2009.12.063 (2009) (Epub ahead of print).
   Google Scholar
• Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey – Adult 2007. Prev. Med.48, 426–431 (2009).
   PubMed Web of Science ®Google Scholar
• Licht AS, Murphy JM, Hyland AJ, Fix BV, Hawk LW, Mahoney MC. Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception? Sex. Trans. Infect.86, 74–78 (2010).
   PubMed Web of Science ®Google Scholar
• Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex. Trans. Infect.85, 499–502 (2009).
   PubMed Web of Science ®Google Scholar
• Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global health. Pub. Health Gen.12, 319–330 (2009).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Ortendahl J, Goldie SJ. Cost–effectiveness of human papillomavirus vaccination and cervical cancer screening in women older that 30 in the United States. Ann. Int. Med.151, 538–555 (2009).
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Sigurdsson K, Iversen O-E et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res.10, 868–878 (2009).
   Google Scholar
• Rodríguez AC, Sciffman M, Herrero R et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. Natl Can. Inst.102, 1–10 (2010).
   Google Scholar
• Palefsky J, Giuliano A, on behalf of the male quadrivalent HPV vaccine efficacy trial study group. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. Presented at: The European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference. Nice, France, 13 November 2008.
   Google Scholar
• Giuliano A, Palefsky J, on behalf of the male quadrivalent HPV vaccine efficacy trial study group. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men. Presented at: The European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference. Nice, France, 13 November 2008.
   Google Scholar
• Kim JJ, Goldie J. Cost–effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Br. Med. J.339, b3884 (2009).
   PubMed Web of Science ®Google Scholar
• Heck JE, Berthiller J, Vaccarella S et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. Int. J. Epidemiol.39, 166–181 (2010).
   PubMed Web of Science ®Google Scholar
• Reiter PL, Brewer NT, McRee A-L, Gilbert P, Smith JS. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex. Trans. Dis.37, 197–203 (2010).
   PubMed Web of Science ®Google Scholar
• Yee LJ, Rhodes SD. Understanding correlates of hepatitis B virus vaccination in men who have sex with men: what have we learned? Sex. Transm. Infect.78, 374–377 (2002).
   PubMed Web of Science ®Google Scholar
• Reiter PL, Brewer NT, Smith JS. HPV knowledge and HPV vaccine acceptability among a national sample of heterosexual males. Sex. Transm. Infect.86, 241–246 (2009).
   PubMed Web of Science ®Google Scholar
• Ferris DG, Waller JL, Miller J et al. Variables associated with human papillomavirus (HPV) vaccine acceptance by men. Am. Board Fam. Med.22, 34–42 (2009).
   PubMed Web of Science ®Google Scholar
• Liddon N, Hood J, Wynn BA, Marlowitz LE. Acceptability of human papillomavirus vaccine for males: a review of the literature. J. Adolesc. Health4, 113–123 (2010).
   Google Scholar
• Gerend MA, Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex. Trans. Dis.36, 58–62 (2009).
   PubMed Web of Science ®Google Scholar
• Nielsen A, Munk C, Liaw K-L, Kjaer SK. Awareness of human papillomavirus in 23,000 Danish men from the general male population. J. Cancer Prev.18, 236–239 (2009).
   PubMedGoogle Scholar
• Ogilivie GS, Remple VP, Marra F et al. Intention of parents to have male children vaccinated with the human papillomavirus vaccine. Sex. Trans. Infect.84, 318–323 (2008).
   PubMedGoogle Scholar
• Jones M, Cook R. Intent to receive an HPV vaccination among university men and women and implications for vaccine administration. J. Am. Coll. Health57, 23–32 (2008).
   PubMed Web of Science ®Google Scholar
• Lacey CJN, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11. Vaccine24(Suppl. 3), 35–41 (2006).
   Web of Science ®Google Scholar
• Woodhall S, Jit M, Cai C et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex. Trans. Dis.36, 515–521 (2009).
   PubMed Web of Science ®Google Scholar
• CDC. STD Treatment Guidelines 2006. MMWR55, RR-11 (2006).
   Google Scholar
• Mortenson GL, Larsen HK. The quality of life of patients with genital warts: a qualitative study. BMC Pub. Health10, 113 (2010).
   PubMedGoogle Scholar
• Waller J, Marlow LAV, Wardle J. Mothers’ attitudes towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol. Biomarkers Prev.15, 1257–1261 (2006).
   PubMed Web of Science ®Google Scholar
• Muňoz N, Kjaer SK, Sigursson K et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl Cancer Inst.102, 325–329 (2010).
   PubMed Web of Science ®Google Scholar
• Neubrand TPL, Breitkopf CR, Rupp R, Breitkpf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clin. Peds.48, 966–969 (2009).
   PubMed Web of Science ®Google Scholar
• Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine28, 989–995 (2010).
   PubMed Web of Science ®Google Scholar
• Robbins SCC, Bernard D, McCaffery K, Brotherton J, Garland S, Skinner SR. “Is cancer contagious?”: Australian adolescent girls and their parents: making the most of limited information about HPV and HPV vaccination. Vaccine28(19), 3398–3408 (2010).
   PubMedGoogle Scholar
• Mathur MB, Mathur VS, Reichling DB. Participation in the decision to become vaccinated against human papillomavirus by California high school girls and the predictors of vaccine status. J. Ped. Health Care24, 14–24 (2010).
   PubMed Web of Science ®Google Scholar
• Agius PA, Pitts MK, Smith AMA, Mitchell A. Human papillomavirus and cervical cancer: Gardasil® vaccination status and knowledge amongst a nationally representative sample of Australian secondary students. Vaccine28, 4416–4422 (2010).
   PubMed Web of Science ®Google Scholar
• Stretch R, Chambers G, Whittaker J et al. Implementing a school-based HPV vaccination programme. Nurs. Times104, 30–33 (2008).
   PubMedGoogle Scholar
• Stretch R, Roberts SA, McCann R et al. Parental attitudes and information needs in an adolescent HPV vaccination programme. Br. J. Cancer99, 1908–1911 (2008).
   PubMed Web of Science ®Google Scholar
• Porta M. The improbable plunge – what facts refute reasons to expect that the effectiveness of HPV vaccine to prevent cervical cancer could be low? Prev. Med.48, 407–410 (2009).
   PubMed Web of Science ®Google Scholar
• Howell-Jones R, Bailey A, Beddows S et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br. J. Cancer103(2), 209–216 (2010).
   PubMed Web of Science ®Google Scholar
• Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol. Oncol.118(1 Suppl.), S12–S17 (2010).
   PubMedGoogle Scholar
• Romanowski B, Schwarz T, Ferguson L et al. HPV-16/18 ASO4-adjuvanted vaccine administered as a 2-dose schedule compared with the standard 3-dose schedule. Presented at: The European Research Organization on Genital Infection and Neoplasia (EUROGIN). Monte Carlo, Monaco, 17–20 February 2009 (Abstract SS 11–15).
   Google Scholar
• Zhang T, Xu Y, Qiao L, Wang Y et al. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine28, 3479–3487 (2010).
   PubMed Web of Science ®Google Scholar
• Jagu S, Karanam B, Gambhira R et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J. Natl CancerInst.101, 782–792 (2009).
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med.361, 1838–1847 (2009).
   PubMed Web of Science ®Google Scholar
• Karanam B, Gambhira R, Peng S et al. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine27, 1040–1049 (2009).
   PubMed Web of Science ®Google Scholar